Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 antibody-blocked autologous RAK cells
- Development stage
- Unknown
- Lead developer
- Everbright
- Modality
- Cell Therapies
01
Overview
PD-1 antibody-blocked autologous RAK cells are an investigational, patient-specific adoptive cell-therapy approach evaluated in a Phase I study for second-line or later advanced non-small cell lung cancer. RAK cells are autologous RetroNectin-activated killer-cell preparations generated from peripheral-blood mononuclear cells; the trial title indicates that the cells are treated with an unspecified PD-1-blocking antibody to reduce PD-1 checkpoint signaling and potentially augment antitumor cytotoxic immune activity. The specific PD-1 antibody, manufacturing process, and a unique product code or INN were not identified in the public trial registration. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=62989))
- Other names
- PD-1 antibody-blocked autologous RAK cellsPD1 antibody-blocked autologous RAK cellsPD 1 antibody-blocked autologous RAK cellsPD-1 antibody-blocked autologous RetroNectin-activated killer cellsPD1 antibody-blocked autologous RetroNectin-activated killer cellsPD 1 antibody-blocked autologous RetroNectin-activated killer cells
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PD-1 antibody-blocked autologous RAK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 antibody-blocked autologous RAK cells.